Menu
Search
|

Menu

Close
X

MEI Pharma Inc MEIP.OQ (NASDAQ Stock Exchange Capital Market)

4.00 USD
-0.04 (-0.99%)
As of Jul 20
chart
Previous Close 4.04
Open 3.88
Volume 141,998
3m Avg Volume 83,422
Today’s High 4.19
Today’s Low 3.88
52 Week High 5.13
52 Week Low 1.79
Shares Outstanding (mil) 70.33
Market Capitalization (mil) 284.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
23
FY16
0
FY15
0
EPS (USD)
FY18
-0.921
FY17
0.067
FY16
-0.606
FY15
-1.234
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
186.55
8.11
Price to Book (MRQ)
vs sector
4.54
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-88.27
13.18
Return on Equity (TTM)
vs sector
-88.27
15.09

EXECUTIVE LEADERSHIP

Christine White
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Daniel Gold
President, Chief Executive Officer, Director, Since 2010
Salary: $552,000.00
Bonus: --
Brian Drazba
Chief Financial Officer, Secretary, Since 2017
Salary: --
Bonus: --
David Urso
Chief Operating Officer, Senior Vice President - Corporate Development, General Counsel, Since 2018
Salary: $352,000.00
Bonus: --
Robert Mass
Chief Medical Officer, Since 2011
Salary: $170,800.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3611 Valley Centre Dr Ste 500
SAN DIEGO   CA   92130-3324

Phone: +1858.7926300

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

SPONSORED STORIES